Last reviewed · How we verify
Non- effervescent Paracetamol kern
Paracetamol inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes in the central nervous system, reducing pain and fever.
Paracetamol inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes in the central nervous system, reducing pain and fever. Used for Mild to moderate pain, Fever reduction.
At a glance
| Generic name | Non- effervescent Paracetamol kern |
|---|---|
| Sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX-1, COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Paracetamol (acetaminophen) acts primarily as a weak inhibitor of COX-1 and COX-2 enzymes, with preferential central nervous system penetration. This reduces prostaglandin production in the brain and spinal cord, leading to analgesic and antipyretic effects. The non-effervescent formulation is a solid oral dosage form without carbonation, designed for conventional swallowing.
Approved indications
- Mild to moderate pain
- Fever reduction
Common side effects
- Hepatotoxicity (at overdose)
- Nausea
- Rash
- Allergic reactions
Key clinical trials
- EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: